Melanoma, Version 2.2013
Daniel G. Coit, Robert H.I. Andtbacka, Christopher James Anker et al. · Journal of the National Comprehensive Cancer Network · 2013
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.
Cited by 155 works. doi:10.6004/jnccn.2013.0055
Authors
- Daniel G. Coit
- Robert H.I. Andtbacka
- Christopher James Anker
- Christopher Keram Bichakjian
- William Edgar Carson
- ADIL I. DAUD
- Dominick J. DiMaio
- Martin D. Fleming
- Valerie Guild
- Allan C. Halpern
- Frank Stephen Hodi
- Mark C. Kelley
- Nikhil I. Khushalani
- Ragini Reiney Kudchadkar
- Julie R. Lange
- Anne C. Lind
- Mary C. Martini
- Anthony J. Olszanski
- Scott Knowles Pruitt
- Merrick I. Ross
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Cancer statistics, 2013
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma